Secondary Stroke Prevention: A Population‐Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence

Faure, Mareva; Castilloux, Anne-Marie; Lillo‐Lelouet, Agnès; Bégaud, Bernard; Moride, Yola

doi:10.1002/cpt.1625

Cited by 5 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Faure et al. ( 2020 ) reported that 36% of patients received ≥2 antiplatelets or a combination of antiplatelet and anticoagulant. Such combinations are not recommended because of the potential increased risk of bleeding (Table S1 ).…”

Section: Resultsmentioning

confidence: 99%

“…11% (95% CI: 2%−19%) of patients did not receive any antithrombotic medications as recommended (Figure 5). Faure et al (2020) reported that 36% of patients received ≥2 antiplatelets or a combination of antiplatelet and anticoagulant. Such combinations are not recommended because of the potential increased risk of bleeding (Table S1).…”

Section: Optimal Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Antithrombotics prescription and adherence among stroke survivors: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Objectives We aimed to investigate the prescription of antithrombotic drugs (including anticoagulants and antiplatelets) and medication adherence after stroke. Methods We performed a systematic literature search across MEDLINE and Embase, from January 1, 2015, to February 17, 2022, to identify studies reporting antithrombotic medications (anticoagulants and antiplatelets) post stroke. Two people independently identified reports to include, extracted data, and assessed the quality of included studies according to the Newcastle–Ottawa scale. Where possible, data were pooled using random‐effects meta‐analysis. Results We included 453,625 stroke patients from 46 studies. The pooled proportion of prescribed antiplatelets and anticoagulants among patients with atrial fibrillation (AF) was 62% (95% CI: 57%–68%), and 68% (95% CI: 58%–79%), respectively. The pooled proportion of patients who were treated according to the recommendation of guidelines of antithrombotic medications from four studies was 67% (95% CI: 41%–93%). It was reported that 11% (95% CI: 2%–19%) of patients did not receive antithrombotic medications. Good adherence to antiplatelet, anticoagulant, and antithrombotic medications was 78% (95% CI: 67%–89%), 71% (95% CI: 57%–84%), and 73% (95% CI: 59%–86%), respectively. Conclusion In conclusion, we found that less than 70% of patients were prescribed and treated according to the recommended guidelines of antithrombotic medications, and good adherence to antithrombotic medications is only 73%. Prescription rate and good adherence to antithrombotic medications still need to be improved among stroke survivors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Optimal Treatmentmentioning

confidence: 99%

Antithrombotics prescription and adherence among stroke survivors: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 35 Compared with the untreated group, patients treated with anticoagulants and antiplatelets had reduced risks of death and recurrence from ischemic stroke (by 73% and 75%, respectively). 36 However, the use of secondary prevention medications for cardiovascular disease (ie, coronary heart disease or stroke) is low worldwide (antiplatelet drugs, 25.3%; β blockers, 17.4%; angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers, 19.5%; and statins, 14.6%), especially in low-income countries and rural areas. 37 The use of antiplatelet and lipid-lowering treatments for secondary prevention has been shown to decline significantly after discharge from hospital in urban areas of China.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Trends in the Stroke Prognosis Among Rural Residents in China: A Population-Based Surveillance Study

Han¹,

Liu²,

Wu³

et al. 2021

RMHP

View full text Add to dashboard Cite

Objective Although stroke mortality has remained stable over the past decade, the long-term trends of stroke burden are scarce in China, especially in low-income populations. Thus, we aimed to explore the secular trends in the prognosis of stroke in a low-income population in China. Methods This was a population-based stroke surveillance study that included all of the participants in the Tianjin Brain Study. Stroke management and outcomes were evaluated for all stroke patients. Trends in the burden of stroke were assessed as annual percentage changes. Results Overall, 1462 stroke cases occurred from 1992 to 2018, and 58.7% of patients were male. The rates of diagnosis by neuroimaging and of hospitalization increased noticeably across sexes and ages for all stroke types, and the greatest increases were observed among elderly women; diagnosis by neuroimaging increased by 4.7% and the rate of hospitalization increased by 12.4% (all P<0.001). Stroke fatality decreased by 3.7% annually among those aged <65 years and by 3.1% among patients aged ≥65 years; the corresponding rates were 7.4% and 3.5%, respectively, for women. The recurrence rate of ischemic stroke significantly decreased among all men, by 9.6% for those aged <65 years and by 3.1% for those aged ≥65 years; however, for women, this rate only significantly decreased for those aged ≥65 years. Conclusion Our findings suggest that the allocation of medical resources has improved over the past decades. However, it is crucial to enhance secondary stroke prevention for women aged <65 years by controlling risk factors in low-income populations.

show abstract

“…After ischemic stroke, the activation of platelets can exacerbate microcirculation disturbances and ischemic brain tissue damage via neurotoxic substances or platelet aggregation. Thrombosis of the common carotid artery in rats can cause transient platelet aggregation, which can significantly expand the cerebral infarction area caused by global cerebral ischemia [35].…”

Section: Inhibiting Platelets and Coagulationmentioning

confidence: 99%

Traditional medicine in China for ischemic stroke: bioactive components, pharmacology, and mechanisms

Xu¹,

Wu²,

Li³

et al. 2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

Ischemic stroke is an acute cerebrovascular disease and the third most common cause of death a ter ischemic heart disease. Increasing attention is being paid to finding e fective treatments through traditional medicine. Thus, studying the traditional medicine for the treatment of ischemic stroke is of great importance. Traditional medicine in China includes traditional Chinese medicine (TCM) and other ethnic medicines, which is rich in variety and resources. This review first introduces the treatment mechanisms associated with ischemic stroke, such as antioxidant nitrification, antiexcitotoxic, antiapoptotic, anti-in lammatory, antiplatelet and anticoagulation mechanisms. Then, we calculated the frequency of prescription use for ischemic stroke and summarized the treatments for ischemic stroke by investigating 13 drug monographs and standards. We found 192 prescriptions from the traditional medical system for ischemic stroke, including Angong Niuhuang pill, Qishiwei Zhenzhu Pills, Ginkgo biloba leaf, and other traditional Chinese patent medicines and national medicines. There were 398 kinds of traditional medicine, including 301 kinds of plant-based medicines, 54 kinds of animal-based medicines, 28 kinds of mineralbased medicines, and 15 kinds of other medicines. We introduced the names, families, medicinal components, traditional uses, phytochemical information, and pharmacological activities of the commonly used Chinese patent medicines and TCMs. In addition, some chemicals were introduced. These medicines may be potential candidates for the treatment of ischemic stroke. This work provides a reference for the research and clinical use of new drugs for ischemic stroke.

show abstract

Secondary Stroke Prevention: A Population‐Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence

Cited by 5 publications

References 39 publications

Antithrombotics prescription and adherence among stroke survivors: A systematic review and meta‐analysis

Antithrombotics prescription and adherence among stroke survivors: A systematic review and meta‐analysis

Long-Term Trends in the Stroke Prognosis Among Rural Residents in China: A Population-Based Surveillance Study

Traditional medicine in China for ischemic stroke: bioactive components, pharmacology, and mechanisms

Contact Info

Product

Resources

About